<DOC>
	<DOCNO>NCT00129961</DOCNO>
	<brief_summary>The purpose study determine effect sirolimus prevention new non-melanoma skin cancer ( NMSC ) kidney transplant recipient .</brief_summary>
	<brief_title>Study Evaluating Effect Sirolimus Non-Melanoma Skin Cancer Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Kidney transplant least 1 year prior Subjects function renal allograft calculate glomerular filtration rate ( GFR ) ≥40mL/min ( Nankivell method ) proteinuria ≤500mg/day . Stable cyclosporine tacrolimusbased multidrug immunosuppressive regimen History NMSC within last 3 year History cancer within last 3 year NMSC metastatic disease 20 NMSC lesion last 12 month Multiple organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
	<keyword>Skin Cancer</keyword>
</DOC>